focus -WSS

focus

author：fashion 2025-08-12 08:29:53 - browse：745

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Hilary expected to bring catastrophic, life

WSS

Inequities make cancer less preventable for women: report

An interview with Robert F. Kennedy Jr. on vaccines

New details revealed about Purdue's marketing of OxyContin

Shingles, which affected Dianne Feinstein, is on the rise

Hilary may become 1st tropical storm to make landfall in California in 84 years

Would Medicare drug price negotiations stall in a shutdown?

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

Mindstrong's demise and the future of mental health care

Hepatitis C has a cure — but many Americans still lack access to it

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Continuity nursing helped my family in our darkest PICU moments

Listen: Who gets the credit for GLP

Bright Health sells Medicare Advantage business to Molina

Beware the threat of staffing cuts at the CDC

Alkermes shareholders re

Baltimore teen accused of firing into crowd during block party mass shooting

focus

Liz Cheney makes 1st public comment since Trump's election interference indictments

Health tech startups drop sharply from 2021 highs

How one patient went off dialysis — and others can too

Biogen shutters digital health group, ends Apple study, in cost cutting move

New definition of a human embryo proposed amid rapid advances

Researchers use wearables data and AI to predict preterm birth risk

leisure time

hotspot

knowledge

leisure time